AI to unlock secrets of overeating and weight gain
NCT ID NCT07637656
First seen Jun 24, 2026 · Last updated Sep 21, 2026 · Updated 60 times
Summary
This study will enroll 800 healthy adults to explore why some people gain weight easily while others do not. Researchers will collect data from blood, urine, body scans, glucose monitors, and eating tests over two years. They will use machine learning to find patterns that predict how much people eat. This is an observational study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal new factors that influence eating habits and weight gain, potentially guiding future weight management strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It aims to find patterns, not test a therapy, so direct health benefits are not expected. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 800 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2037
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
800 males and females, age 18-60 years who are in good health
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: To be eligible to participate in this study, an individual must meet all the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Age 18 to 60 3. In good general health as evidenced by medical history and physical exam EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Weight \>=204 kg (\>=450 pounds, maximum weight of the iDXA machine as per manufacturer s manual), or weight \<45.4 kg (\<100 pounds, minimum weight allowed based on the NIH guidelines of blood drawing for research purposes) 2. Unstable weight (+/-5%) within past 6 months as determined by volunteer self-report. 3. Current use of medications, dietary supplements, or alternative therapies known to alter energy metabolism 4. Inability to consume provided food based on food allergy or intolerance or other food restrictions (e.g., kosher, vegan, or vegetarian) 5. Current pregnancy, or recent pregnancy within past 6 months or currently lactating 6. History or clinical manifestation of: 6i. Diabetes, including fasting glucose \>= 126 mg/dl or HbA1c \>= 6.5%, or history 6ii. Surgery for treatment of obesity 6iii. Endocrine disorders, such as Cushing s disease, pituitary disorders, or hypo- and hyperthyroidism (TSH \<0.1 or \>= 10 uIU/mL) 6iv. Pulmonary disorders including chronic obstructive pulmonary disease or other lung disease that which would limit ability to follow the protocol 6v. History of coronary artery disease, heart failure, arrhythmias, and peripheral artery disease that which would limit ability to follow the protocol 6vi. Liver disease, including cirrhosis, active hepatitis B or C based on history, and AST or ALT \>= 3x normal 6vii. Gastrointestinal disease including Crohn's disease, ulcerative colitis, celiac disease, or other malabsorptive disorders by history 6viii. Hematologic disorders including significant anemia (male hemoglobin \< 13.0 g/dL or female hemoglobin \< 11.0 g/dL) 6ix. Renal disease including abnormal kidney function (eGFR \<60 mL/min/1.73m\^2) 6x. Central nervous system disease, including cerebrovascular accidents, dementia, and neurodegenerative disorders by history 6xi. Cancer requiring treatment in the past 5 years, except for nonmelanoma skin cancers or cancers that have clearly been cured 6xii. Infectious disease such as active tuberculosis, HIV (by self-report), chronic coccidiomycosis or other chronic infections that might influence appetite 6xiii. Diagnosis of binge eating disorder, anorexia, or major psychiatric disorders including depression, schizophrenia, and psychosis 6xiv. Menopausal transition (late) to early postmenopause (e.g., \>= 2 skipped cycles and an interval of amenorrhea \>= 60 days and \<12 months) 7\. Alcohol abuse as defined by \>= 8-point score on the Alcohol Use Disorders Identification Test (AUDIT) questionnaire interview 8\. Inability to provide informed consent 9\. Any disorder, unwillingness, or inability not specifically mentioned above may serve as criteria for exclusion at the discretion of the investigators, such as those that jeopardize the safety of the participant or others, or would interfere with completion of study procedures
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
NIDDK, Phoenix
Phoenix, Arizona, 85014, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental brain drug TAK-935 put to the test in healthy volunteers
- Tracing a Low-THC cannabis extract through the human body
- Can a new injection SGB-9768 pass its first safety test?
- Can a new PET tracer reveal the Body's hidden stress?
- Zapping the brain to shift Decision-Making in depression and aging
- Can a new formula make omega-3 and vitamin D3 supplements work better?